Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy Omission in Gastric Cancer Responders
NCT06942663Phase 2Not yet recruiting
- Sponsor
- Nizhny Novgorod Regional Clinical Oncology Center
- Start
- Apr 2025
- Primary completion
- Nov 2027
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of fluorouracil, oxaliplatin, docetaxel in gastric cancer (GC), sponsored by Nizhny Novgorod Regional Clinical Oncology Center. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
fluorouraciloxaliplatindocetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06942663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942663.